Transcenta Holding Limited, a global biotherapeutics company, announced on Wednesday that it has named Dr Michael Shi as its new executive vice president, head of Global R&D and chief medical officer.

In the new role, Dr Shi is to head the global research and development of all pipeline molecules and registration approvals.

Dr Shi has served as global program clinical head at Novartis Pharmaceuticals Corporation in East Hanover, New Jersey, USA. He has held the position of program director of Genetics Variation at NIH and an assistant professor at the University of Michigan Medical School. He received his medical education from Peking Union Medical College, a PhD in Molecular Pharmacology and Toxicology from the University of Southern California and conducted a postdoctoral fellowship at Harvard Medical School.